Syndax Appoints Dr. Briggs W. Morrison as Chief Executive Officer and Michael A. Metzger as President and Chief Operating Officer
June 15, 2015Syndax Pharmaceuticals announced today that Briggs W. Morrison, M.D. is joining as CEO and board member and Michael A. Metzger is joining as President and COO. This new executive team will intensify focus on innovation and leadership in immuno-oncology.
More »
Esperion Therapeutics Announces the Appointment of Scott Braunstein, M.D. to Board of Directors
June 15, 2015Esperion Therapeutics appoints Scott Braunstein, M.D. to its board of directors as a Class III Director, with a term expiring at the 2016 annual meeting of stockholders.
More »
Milestone Pharmaceuticals Closes US$17 Million Series B Financing to Complete Phase 2 Clinical Studies for MSP-2017
June 15, 2015Milestone Pharmaceuticals closes a $17 million Series B financing led by Domain Associates to complete Phase 2 clinical development of MSP-2017. In connection with this financing, Domain’s Debra Liebert will join Milestone’s board of directors.
More »